Open access · CC-BY
via OpenAlex
NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
Tianbao Wang, Xue Zhou, Xinhua Chen
Frontiers in Neurology · 2026
Genomic instability
Epigenetic alterations
Loss of proteostasis
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Disabled macroautophagy
Human
Review
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide, characterized by the progressive loss of dopaminergic neurons in the substantia nigra, accumulation of α-synuclein (α-syn), mitochondrial dysfunction(definition), and neuroinflammation. Nicotinamide adenine dinucleotide (NAD + ), a crucial coenzyme involved in cellular energy metabolism, DNA repair, and epigenetic regulation, declines with aging and is markedly reduced in the brains of patients with PD. Emerging evidence suggests that supplementation with NAD + precursors, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), exerts neuroprotective effects through multiple mechanisms, such as activation of the mitochondrial unfolded protein response (UPR∧mt), enhancement of autophagy(definition), and suppression of excessive poly(ADP-ribose) polymerase 1 (PARP1) activation. This review summarizes the central role of NAD + dysregulation in the pathogenesis of PD, with particular emphasis on the interplay between NAD + depletion, mitochondrial quality control, proteostasis(definition), and neuroinflammation. Furthermore, we discuss recent advances in NAD + -boosting strategies in PD models and clinical studies, highlighting their potential therapeutic implications for PD intervention.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fneur.2026.1943801
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
Wang, T., Zhou, X., & Chen, X. (2026). NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives. <em>Frontiers in Neurology</em>. https://doi.org/10.3389/fneur.2026.1943801
Vancouver
Wang T, Zhou X, Chen X. NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives. Frontiers in Neurology. 2026. doi:10.3389/fneur.2026.1943801.
BibTeX
@article{tianbao2026NADsig,
title = {NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives},
author = {Tianbao Wang and Xue Zhou and Xinhua Chen},
journal = {Frontiers in Neurology},
year = {2026},
doi = {10.3389/fneur.2026.1943801},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in neurology 2026
Citation only
NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives.
PubMed 2016
Preprint
The pathophysiological importance and therapeutic potential of NAD' biosynthesis and mitochondrial sirtuin SIRT3 in age-associated diseases.
Current Opinion in Cardiology 2026
Citation only
Role of nicotinamide adenine dinucleotide in cardiovascular disease
Current opinion in cardiology 2026
Citation only
Role of nicotinamide adenine dinucleotide in cardiovascular disease.
Frontiers in neurology
Open access · OA
NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
bioRxiv (Cold Spring Harbor Laboratory) 2020
Preprint · CC-BY